Skip to content

Fulgent Genetics, Inc. FLGT Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Quest Diagnostics logo
Quest DiagnosticsDGX
$65M+124%
NeoGenomics logo
NeoGenomicsNEO
-$338K-136%
Natera, Inc. logo
Natera, Inc.NTRA
$3.86M+610%
GeneDx Holdings logo
GeneDx HoldingsWGS
$476K
Personalis, Inc. logo
Personalis, Inc.PSNL
$20.95M+17.8%
Veracyte logo
VeracyteVCYT
$2.74M-7.8%

Other financials

Income statement

See full
Revenue$71.1M-3.2%
Gross profit$21.5M-24.2%
Operating income-$34.6M-74.9%
Net income-$24.8M-115%
EPS (diluted)-$0.80-116%

Balance sheet

See full
Cash & equivalents$23.4M-65.2%
Total debt$8.2M+40.5%
Total equity$1.0B-6.9%
Total assets$1.2B-4.1%

Cash flow

See full
Operating cash flow$7.1M+260%
CapEx$5.2M+10.3%
Free cash flow$1.9M+121%

Valuation

See full
Market cap$552.11M-7.1%
Enterprise value$536.92M+0.7%
P/S1.7×-0.3×

Profitability

See full
Gross margin38.7%-0.1pp
Operating margin-33.1%+17.4pp
Net margin-23%+43.3pp
FCF margin-36.9%

Returns & leverage

See full
Return on equity-6.8%+48.2pp
Debt / equity0.0×
Current ratio5.3×-1.0×

Where this comes from

Reported directly by Fulgent Genetics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Fulgent Genetics, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Fulgent Genetics, Inc.'s stock issuance proceeds?
Fulgent Genetics, Inc. (FLGT) reported stock issuance proceeds of $9K in Q1 2026.
What is the long-term trend for Fulgent Genetics, Inc.'s stock issuance proceeds?
Over 3 years (2021 to 2024), Fulgent Genetics, Inc.'s stock issuance proceeds has grown at a -91.7% compound annual growth rate (CAGR), from $89.51M to $51K.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.